ASX CODE: PAR
Paradigm Biopharmaceuticals’ iPPS drug reduces bone marrow lesions in hip, knee caps and ankles
As it advances its injectable Pentosan Polysulfate (iPPS) drug towards commercialisation, Paradigm Biopharmaceuticals (ASX: PAR) has noted a clinically meaningful decrease in bone marrow...
Paradigm Biopharma’s knee osteoarthritis trial meets secondary endpoints, launches capital raise
Paradigm Biopharmaceuticals (ASX: PAR) has announced trial patients being treated with its injectable pentosan polysulfate sodium (iPPS) drug for osteoarthritis of the knee have...
International symposium sets scene for Paradigm Biopharmaceuticals’ MPS trial
Paradigm Biopharmaceuticals (ASX: PAR) has set its sights on applying to the US Food and Drug Administration (FDA) to begin a clinical trial for...
Paradigm Biopharmaceuticals meets primary endpoints in Phase 2b knee osteoarthritis trial
Paradigm Biopharmaceuticals (ASX: PAR) has confirmed the potential of its injectable pentosan polysulfate sodium (iPPS) drug to be “safe and effective” in treating knee...
Paradigm Biopharmaceuticals reasserts osteoarthritis pain reduction results
Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has reasserted its previously published figures relating to pain reduction resulting from its flagship drug treatment Pentosan Polysulfate Sodium...
Paradigm Biopharmaceuticals to deploy iPPS to treat rare joint disease
Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) is continuing to expand the gamut of applications for its proprietary Pentosan Polysulfate Sodium (iPPS) drug by signing an agreement...
Australian Government numbs capital expenditure pain for Paradigm Biopharmaceuticals
Biotechnology company Paradigm Biopharmaceuticals (ASX: PAR) has received a further boost in its mission to bring a potentially industry-leading chronic pain medication to the Australian...
Paradigm’s injectable osteoarthritis drug trial shows major reduction in chronic pain
Australian biotech company Paradigm Pharmaceuticals (ASX: PAR) has reported an average 51.2% reduction in chronic knee pain by a group of osteoarthritis patients being...
Paradigm Biopharmaceuticals looks to touchdown its osteoarthritis drug in the United States
Paradigm Biopharmaceuticals (ASX: PAR) has struck a strategic partnership with the Pro Players’ Elite Network (PPEN), a US-based retired professional sporting network comprised of...
Paradigm Biopharmaceuticals looks to scale summit of chronic pain reduction
Biotech company Paradigm Biopharmaceuticals (ASX: PAR) continues to make progress on its mission of developing a radical shift in reducing chronic joint pain from osteoarthritis.
With...
Paradigm Biopharma weathers seasonal change to complete recruitment for Ross River virus study
Paradigm Biopharmaceuticals (ASX: PAR) has completed the recruitment stage of its phase 2a clinical trial in participants with persistent ‘Ross River virus (RRV) induced...
Paradigm Biopharma raises the stakes in osteoarthritis pain reduction
Biotech company Paradigm Biopharmaceuticals (ASX: PAR) has announced further progress in its bid to develop a definitive pain reduction treatment for both elite athletes...
